title: Plasma dehydroepiandrosterone and risk of myocardial infarction in women.
abstract: BACKGROUND
  In this study we prospectively evaluated the relationships between plasma concentrations of dehydroepiandrosterone (DHEA) and dehydroepiandrosterone sulfate (DHEA-S) and subsequent myocardial infarction in women.
  
  
  METHODS
  Using case-control sampling, we selected participants from the Nurses' Health Study cohort. Blood samples were collected from 1989 to 1990 when the women were 43 to 69 years old. During follow-up through June 1998, 239 women were diagnosed with myocardial infarction (fatal and nonfatal). We matched cases 1:2 by age, cigarette smoking status, fasting status, and month of blood collection and used conditional logistic regression to adjust for potential confounders, including anthropometric factors and dietary intake.
  
  
  RESULTS
  Baseline median (10th, 90th percentiles) concentrations of DHEA were 17.1 (4.3, 46.7) nmol/L among women who subsequently developed myocardial infarction and 16.6 (6.1, 37.9) among controls. The risk of myocardial infarction increased with plasma concentrations of DHEA and its sulfate. Women in the highest DHEA quartile had a rate ratio (RR) of 1.27 (95% CI 0.92-1.74, P for trend = 0.008) for myocardial infarction compared with those in the lowest quartile, after adjusting for covariates. The results did not vary significantly by menopausal status, postmenopausal estrogen therapy, fasting status, or age at time of blood collection. Similar relationships between concentrations of DHEA-S and risk were observed, with an RR of 1.58 (95% CI 1.13-2.21; P for trend = 0.06) for myocardial infarction in the highest vs lowest quartile.
  
  
  CONCLUSIONS
  We observed a modest positive relationship between plasma concentrations of DHEA and its sulfate and the risk of subsequent myocardial infarction among predominantly postmenopausal women.
authors.affiliation: Department of Epidemiology, Harvard School of Public Health, Boston, MA 02115, USA. jpage@hsph.harvard.edu
authors.forename: John H
authors.initials: JH
authors.lastname: Page
authors.forename: Jing
authors.initials: J
authors.lastname: Ma
authors.forename: Kathryn M
authors.initials: KM
authors.lastname: Rexrode
authors.forename: Nader
authors.initials: N
authors.lastname: Rifai
authors.forename: Joann E
authors.initials: JE
authors.lastname: Manson
authors.forename: Susan E
authors.initials: SE
authors.lastname: Hankinson
mesh_terms: D000328:Adult; D000367:Age Factors; D015415:Biomarkers / Q000097:blood; D016022:Case-Control Studies; D003687:Dehydroepiandrosterone / Q000097:blood*; D019314:Dehydroepiandrosterone Sulfate / Q000097:blood; D015914:Estrogen Replacement Therapy; D005215:Fasting; D005260:Female; D006801:Humans; D008875:Middle Aged; D009203:Myocardial Infarction / Q000453:epidemiology*; D010949:Plasma; D017698:Postmenopause; D011446:Prospective Studies; D012306:Risk
chemical_list: D015415:Biomarkers; D003687:Dehydroepiandrosterone; D019314:Dehydroepiandrosterone Sulfate